

# Subject Index

**A**  
Acute phase reactant protein 38

Adjuvant  
- Manganese 118

Alloantigen 44

Antibody  
- Choriogonadotropin 2  
- Conjugates 185  
- Natural 89  
- Anti-tumor 134

Antigen

- Heterogeneity 69  
- Mammary tumor 98  
Aspergillus fumigatus 145

Autoantigen

- Breast Cancer 153

**B**  
BCG 85, 130, 164, 174, 182, 198

BCNU 128

Bladder carcinoma 89

Breast cancer 153

**C**  
Candida albicans 128

Carcinogenesis  
- Chemical 125

Chemoimmunotherapy 5, 128

Chemotaxis 93

Choriogonadotropin 2

**F**  
5-Fluorouracil 182

**G**  
Gastric cancer 105, 182, 190

**H**  
Hepatitis A Virus 53  
Hepatocellular carcinoma 53

**I**  
Immune complexes 44, 153  
Immunogenicity  
- Tumor 194  
Immunoselection 194  
Immunosuppression 38  
Immunotherapy 5, 75, 85, 174  
Interferon 56, 149, 158

**L**  
Levamisole 24, 140  
Leukemia 56, 85

Lung cancer 93, 140, 164, 174

Lymphocytes  
- Cytotoxicity 14, 30, 56  
Lymphoma  
- Murine 128

**M**  
Macrophage 98, 112, 145

Mammary tumor 98

Manganese

- Adjuvant 118  
Melanoma 69  
Mitomycin C 112  
Monoclonal antibody 69  
Monocytes  
- Blood 93, 149, 190

**N**  
Natural cytotoxicity 14

Natural resistance 125

NK cells 24, 125, 158

**O**  
Opsinization 176

**P**  
Platelet  
- Alloantigen 44  
Poly I:C 158


**R**  
Regional immunotherapy 174

**S**  
Suppressor factor 134

**T**  
T cell  
- Growth factor 5, 14  
- Suppressors 105  
Tumor immunity  
- Antigen reactive cell 176  
- Vaccines 75, 118

**V**  
Vaccines  
- Cell 85  
- Tumor 75, 118  
Virus  
- Hepatitis A 53

**X**  
Xeonantisera 48, 69







# Cancer Immunology Immunotherapy

Other Biological Response Modifications

Volume 13 1982

## Editors in Chief

**R. W. Baldwin G. Mathé E. Mihich**

## Editorial Board

**M. Boranic** Zagreb

**E. C. Borden** Madison

**P. Burtin** Villejuif

**J.-C. Cerottini** Epalinges

**G. Della Porta** Milano

**F. Deinhardt** Munich

**S. Dray** Chicago

**S. Ferrone** New York

**A. Goldstein** Washington

**R. Good** New York

**K. Hellstrom** Seattle

**R. Herberman** Bethesda

**L. Israël** Bobigny

**K. Karrer** Vienna

**G. Klein** Stockholm

**H. Kobayashi** Sapporo

**A. LoBuglio** Ann Arbor

**M. Mastrangelo** Philadelphia

**P. Minden** Denver

**D. Morton** Los Angeles

**H. M. Pinedo** Amsterdam

**R. Oldham** Frederick

**P. Reizenstein** Stockholm

**G. Riethmüller** Munich

**M. Rittenberg** Portland

**B. Serrou** Montpellier

**J. Stjernswärd** Geneva

**H. Umezawa** Tokyo

**D. W. van Bekkum** Rijswijk

**N. Warner** Mountain View

**D. Weiss** Jerusalem

**M. F. A. Woodruff** Edinburgh

**Y. Yagi** Kamakura City

**K. Yamamoto** Kanazawa

**Y. Yamamura** Osaka



Springer International

## Cancer Immunology and Immunotherapy

### Other Biological Response Modifications

This journal was founded in 1976. Editors: R. W. Baldwin, G. Mathé, E. Mihich. Published by Springer International.

The exclusive copyright for all languages and countries, including the right for photomechanical and any other reproductions, also in microform, is transferred to the publisher.

The use of registered names, trademarks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use.

Authors of this journal can benefit from library and photocopy fees collected by VG WORT if certain conditions are met. If an author lives in the Federal Republic of Germany or in West Berlin it is recommended that he contacts Verwertungsgesellschaft WORT, Abteilung Wissenschaft, Goethestraße 49, D-8000 München 2, for detailed information.

Die Wiedergabe von Gebrauchsnamen, Handelsnamen, Warenbezeichnungen usw. in dieser Zeitschrift berechtigt auch ohne besondere Kennzeichnung nicht zu der Annahme, daß solche Namen im Sinne der Warenzeichen- und Markenschutz-Gesetzgebung als frei zu betrachten wären und daher von jedermann benutzt werden dürfen.

Die in der Zeitschrift veröffentlichten Beiträge sind urheberrechtlich geschützt. Alle Rechte, insbesondere das der Übersetzung in fremde Sprachen, vorbehalten. Kein Teil dieser Zeitschrift darf ohne schriftliche Genehmigung des Verlages in irgendeiner Form – durch Fotokopie, Mikrofilm oder andere Verfahren – reproduziert oder in einer von Maschinen, insbesondere von Datenverarbeitungsanlagen, verwendbare Sprache übertragen werden.

Auch die Rechte der Wiedergabe durch Vortrag, Funk- und Fernsehsendung, im Magnettonverfahren oder ähnlichem Wege bleiben vorbehalten.

Fotokopien für den persönlichen und sonstigen eigenen Gebrauch dürfen nur von einzelnen Beiträgen oder Teilen daraus als Einzelkopien hergestellt werden. Jede im Bereich eines gewerblichen Unternehmens hergestellte oder benutzte Kopie dient gewerblichen Zwecken gem. § 54 (2) UrhG und verpflichtet zur Gebührenzahlung an die VG WORT, Abteilung Wissenschaft, Goethestraße 49, D-8000 München 2, von der die einzelnen Zahlungsmodalitäten zu erfragen sind.

Autoren dieser Zeitschrift können unter gewissen Voraussetzungen in die Individualauschüttung von Mitteln aus der Bibliothektausgabe und dem Fotokopieraufkommen mit einzbezogen werden. Genaue Informationen erteilt die Verwertungsgesellschaft WORT, Abteilung Wissenschaft, Goethestraße 49, D-8000 München 2.

Springer-Verlag Berlin Heidelberg New York

Printers: Carl Ritter GmbH & Co. KG, Wiesbaden

Printed in Germany · © Springer-Verlag Berlin Heidelberg 1982

## Table of Contents

**Acevedo, H. F.,** see Kellen, J. A., et al. 2

**Baccarini, M.,** see Marconi, P., et al. 128

**Baker, M. A.,** see Oldham, R. K., et al. 164

**Baker, M. A., Taub, R. N., Carter, W. H. and the Toronto Leukemia Study Group:** Immunotherapy for Remission Maintenance in Acute Myeloblastic Leukemia 85

**Bennedsen, J.,** see Nielsen, H., et al. 93

**Bistoni, F.,** see Marconi, P., et al. 128

**Blair, A. H.,** see Ghose, T., et al. 185

**Boizard, B.,** see Wautier, J. L., et al. 44

**Bonavida, B.,** see Hutchinson, I. V. 176

**Bonmassar, E.,** see Marconi, P., et al. 128

**Borden, E. C.,** see Edwards, B. S., et al. 158

**Borden, E. C.,** see Liberati, A. M., et al. 140

**Bosslet, K.,** see Schirrmacher, V. 62

**Bowlin, T. L., Proffitt, M. R.:** The Immune Response to a Chemically Induced Fibrosarcoma: A Comparison of Cytolytic T Lymphocyte Stimulation by Transformed and Non-Transformed Fibroblasts 30

**Brodt, P., Gordon, J.:** Natural Resistance Mechanisms May Play a Role in Protection Against Chemical Carcinogenesis 125

**Bryan, G. T.,** see Liberati, A. M., et al. 140

**Caen, J. P.,** see Wautier, J. L., et al. 44

**Carter, W. H.,** see Baker, M. A., et al. 85

**Cassone, A.,** see Marconi, P., et al. 128

**Citrin, D. L.,** see Liberati, A. M., et al. 140

**Coates, A. S.,** see Liberati, A. M., et al. 140

**Cokerell, G. L., O'Donnell, R. W., Zgola, M. M.:** The Immunopathological Effects of Intracolonic Injection of *Mycobacterium bovis* BCG Cell Wall Emulsions in Guinea Pigs 198

**Czupryna, A.,** see Mytar, B., et al. 190

**Dawson, J. R.,** see Shau, H. 24

**Deinhardt, F.,** see Gauss-Müller, V., et al. 53

**deKernion, J. B., Lovrekovich, L.:** Antitumor Effect of Heat-Killed *Aspergillus fumigatus* Mycelium in a Mouse Model 145

**Doan, R.,** see Wautier, J. L., et al. 44

**Dombernowsky, P.,** see Nielsen, H., et al. 93

**Eberlein, T. J., Rosenstein, M., Spiess, P., Wesley, R., Rosenberg, S. A.:** Adoptive Chemoimmunotherapy of a Syngeneic Murine Lymphoma with Long-Term Lymphoid Cell Lines Expanded in T Cell Growth Factor 5

**Edelstein, R.,** see Samak, R., et al. 38

**Edwards, B. S., Borden, E. C., Smith-Zaremba, K.:** Divergence in Activation by Poly I:C of Human Natural Killer and Killer Cells 158

**Einhorn, S., Jarstrand, C.:** Decrease in the Phagocytic Activity of Peripheral Monocytes in Patients Treated with Human Interferon- $\alpha$  149

**Ferguson, R.,** see Vose, B. M., et al. 105

**Ferrone, S.,** see Wilson, B. S., et al. 69

**Forbes, J. T.,** see Oldham, R. K., et al. 164

**Frati, L.,** see Marconi, P., et al. 128

**Gail, M. H.,** see Oldham, R. K., et al. 164

**Garaci, E.,** see Marconi, P., et al. 128

**Gauss-Müller, V., Deinhardt, F., Hahn, E., Lamerz, R.:** Hepatitis A Virus Infection of HBsAg-Producing Hepatocellular Carcinomas in Athymic Mice 53

**Ghose, T., Guclu, A., Raman, R. R., Blair, A. H.:** Inhibition of a Mouse Hepatoma by the Alkylating Agent Trenimon Linked to Immunoglobulins 185

**Gilead, Z., Hatzubai, A., Sulitzeanu, D.:** Antigens in Immune Complexes from Patients with Breast Cancer: Identification of Autoantigens in Immune Complexes Isolated from Breast Cancer Effusions 153

**Gordon, J.,** see Brodt, P. 125

**Gorelik, E.,** see Kedar, E., et al. 14

**Grossman, H. B.:** Natural Antibody to a Human Bladder Carcinoma Cell Line 89

**Guclu, A.,** see Ghose, T., et al. 185

**Hahn, E.,** see Gauss-Müller, V., et al. 53

**Hartmann, L.,** see Wautier, J. L., et al. 44

**Hatzubai, A.,** see Gilead, Z., et al. 153

**Heineman, W.,** see Oldham, R. K., et al. 164

**Herberman, R. B.,** see Kedar, E., et al. 14

**Hersh, E.,** see Oldham, R. K., et al. 164

**Holmes, E. C.,** see Oldham, R. K., et al. 164

**Hutchinson, I. V., Bonavida, B.:** Opsonization of Tumor-Reactive T Cells in SJL/J Mice Bearing Syngeneic Tumors 176

**Ikejiri, B. L.,** see Kedar, E., et al. 14

**Imai, K.,** see Wilson, B. S., et al. 69

**Inoue, T.,** see Ogura, T., et al. 112

**Israel, L.,** see Samak, R., et al. 38

**Jarstrand, C.,** see Einhorn, S. 149

**Jedrychowski, W.,** see Popielka, T., et al. 182

**Kahan, B. D.,** see Tanaka, T., et al. 48

**Kanor, S.,** see Sianetz, C. A., Jr., et al. 75

**Kay, N. E.,** see Wilson, B. S., et al. 69

**Kedar, E., Ikejiri, B. L., Gorelik, E., Herberman, R. B.:** Natural Cell-Mediated Cytotoxicity in vitro and Inhibition of Tumor Growth in vivo by Murine Lymphoid Cells Cultured with T Cell Growth Factor (TCGF) 14

**Kellen, J. A., Kolin, A., Mirakian, A., Acevedo, H. F.:** Effects of Antibodies to Choriogonadotropin in Malignant Growth: II. Solid Transplantable Rat Tumors 2

**Kishimoto, S.,** see Ogura, T., et al. 112

**Kolin, A.,** see Kellen, J. A., et al. 2

**Laing, C. A.:** Kinetics of the Reactivity of Subpopulations of Spleen Cells of Mice Bearing Virus-Induced Mammary Tumors to Syngeneic Antigenic Extracts in vitro. Supportive and Suppressive Effects of Macrophages 98

**Lamerz, R.,** see Gauss-Müller, V., et al. 53

**Lang, J. M.,** see Roeslin, N., et al. 174

**Larsen, S. O.,** see Nielsen, H., et al. 93

**Lawler, E. M., Prehn, R. T.:** Influence of Immune Status of Host on Immunogenicity of Tumors Induced with Two Doses of Methylcholanthrene 194

**Levy, J. G.,** see Maier, T. 134

**Liberati, A. M., Voelkel, J. G., Borden, E. C., Coates, A. S., Citrin, D. L., Bryan, G. T.:** Influence of Non-Specific Immunologic Factors on Prognosis in Advanced Bronchogenic Carcinoma 140

**Lovrekovich, L.,** see deKernion, J. B. 145

**Lung Cancer Study Group,** see Oldham, R. K., et al. 164

**Maier, T., Levy, J. G.:** Anti-Tumor Effects of an Antiserum Raised in Syngeneic Mice to a Tumor-Specific T Suppressor Factor 134

**Marconi, P., Bistoni, F., Cassone, A., Frati, L., Baccarini, M., Garaci, E., Bonmassar, E.:** The Role of the Peritoneal Cavity in Successful Treatment of a Murine Lymphoma with Chemotherapy and Non-Specific Immunostimulation 128

**Masuno, T.,** see Ogura, T., et al. 112

**McCollester, D. L.:** Manganese Potentiation of Autologous Anti-Meth A Tumor Vaccines. A Developmental Study 118

**McCollester, D. L.,** see Sianetz, C. A., Jr., et al. 75

**Mirakian, A.,** see Kellen, J. A., et al. 2

**Moore, M., Taylor, G. M., White, W. J.:** Susceptibility of Human Leukemias to Cell-Mediated Cytotoxicity by Interferon-Treated Allogeneic Lymphocytes 56

**Moore, M.,** see Vose, B. M., et al. 105

**Morand, G.,** see Roeslin, N., et al. 174

**Mytar, B., Zembala, M., Uracz, W., Czupryna, A.:** Cytostatic Activity on Tumour Cells of Monocytes from Patients with Gastrointestinal Cancer 190

**Namba, M.,** see Ogura, T., et al. 112

**Nielsen, H., Bennedsen, J., Larsen, S. O., Dombernowsky, P., Viskum, K.:** A Quantitative and Qualitative Study of Blood Monocytes in Patients with Bronchogenic Carcinoma 93

**O'Donnell, R. W.,** see Cockerell, G. L., et al. 198

**Ogura, T., Shindo, H., Shinzato, O., Namba, M., Masuno, T., Inoue, T., Kishimoto, S., Jamamura, J.:** In vitro Tumor Cell Killing by Peritoneal Macrophages from Mitomycin C-Treated Rats 112

**Oldham, R. K., Gail, M. H., Baker, M. A., Forbes, J. T., Heine-man, W., Hersh, E., Holmes, E. C., Ritts, R. E., Wright, P. W., and the Lung Cancer Study Group:** Immunological Studies in a Double Blind Randomized Trial Comparing Intrapleural BCG Against Placebo in Patients with Resected Stage I Non-Small Cell Lung Cancer 164

**Oszacki, J.,** see Popiela, T., et al. 182

**Pellis, N. R.,** see Tanaka, T., et al. 48

**Popiela, T., Zembala, M., Oszacki, J., Jędrychowski, W.:** A Follow-Up Study on Chemoimmunotherapy (5-Fluorouracil and BCG) in Advanced Gastric Cancer 182

**Prehn, R. T.,** see Lawler, E. M. 194

**Profitt, M. R.,** see Bowlin, T. L. 30

**Raman, R. R.,** see Ghose, T., et al. 185

**Ritts, R. E.,** see Oldham, R. K., et al. 164

**Roeslin, N., Lang, J. M., Morand, G., Wihlm, J. M., Witz, J. P.:** Regional Immunotherapy in Resectable Squamous Cell Lung Carcinoma: Analysis of a Randomized Study 174

**Rosenberg, S. A.,** see Eberlein, T. J., et al. 5

**Rosenstein, M.,** see Eberlein, T. J., et al. 5

**Samak, R., Edelstein, R., Israel, L.:** Immunosuppressive Effect of Acute-Phase Reactant Proteins in vitro and Its Relevance to Cancer 38

**Schirrmacher, V., Bosslet, K.:** Clonal Analysis of Expression of Tumor-Associated Transplantation Antigens and of Metastatic Capacity 62

**Shau, H., Dawson, J. R.:** Regulation of Human Natural Killing by Levamisole 24

**Shindo, H.,** see Ogura, T., et al. 112

**Shinzato, O.,** see Ogura, T., et al. 112

**Sianetz, C. A. Jr., McCollester, D. L., Kanor, S.:** Autologous Anticancer Antigen Preparation for Specific Immunotherapy in Advanced Cancer Patients. A Phase I Clinical Trial 75

**Smith-Zaremba, K.,** see Edwards, B. S., et al. 158

**Spiess, P.,** see Eberlein, T. J., et al. 5

**Sulitzeanu, D.,** see Gilead, Z., et al. 153

**Tanaka, T., Yamagishi, H., Pellis, N. R., Kahan, B. D.:** Production of a Tumor-Specific Xenoantiserum from Partially Purified Immunoprotective Tumor Antigen 48

**Taub, R. N.,** see Baker, M. A., et al. 85

**Taylor, G. M.,** see Moore, M., et al. 56

**Toronto Leukemia Study Group,** see Baker, M. A., et al. 85

**Uracz, W.,** see Mytar, B., et al. 190

**Viscum, K.,** see Nielsen, H., et al. 93

**Voelkel, J. G.,** see Liberati, A. M., et al. 140

**Vose, B. M., Ferguson, R., Moore, M.:** Mitogen Responsiveness and Inhibitory Activity of Mesenteric Lymph Node Cells. Conditioned Medium Containing T Cell Growth Factor Reverses Suppressor Function 105

**Wautier, J. L., Boizard, B., Doan, R., Caen, J. P., Hartmann, L.:** Identification of the Platelet Alloantigen (P1A1) in Circulating Immune Complexes of Normal Human Sera 44

**Wesley, R.,** see Eberlein, T. J., et al. 5

**White, W. J.,** see Moore, M., et al. 56

**Wihlm, J. M.,** see Roeslin, N., et al. 174

**Wilson, B. S., Kay, N. E., Imai, K., Ferrone, S.:** Heterogeneity of Human Melanoma-Associated Antigens Defined by Monoclonal Antibodies and Conventional Xenoantiserum 69

**Witz, J. P.,** see Roeslin, N., et al. 174

**Wright, P. W.,** see Oldham, R. K., et al. 164

**Yamagishi, H.,** see Tanaka, T., et al. 48

**Jamamura, J.,** see Ogura, T., et al. 112

**Zembala, M.,** see Mytar, B., et al. 190

**Zembala, M.,** see Popiela, T., et al. 182

**Zgola, M. M.,** see Cockerell, G. L., et al. 198

ession  
and of

Kill-

gous  
mono-  
nical

roduc-  
tially

l. 85

nsive-  
Node  
rowth

an, L.:  
culat-  
44

neity  
ed by  
oanti-